Eli Lilly posts promising PhIII migraine results, but settles into the pack in the last leg of the race to the FDA
Eli Lilly $LLY is lining up its application for its CGRP migraine drug galcanezumab after racking up a slate of date from three Phase III studies that puts it right alongside its many rivals. The headline success was heralded weeks ago, with the details unveiled Saturday at the American Headache Society annual scientific meeting in Boston.
CGRP drugs look like a safe way to lower the number of migraine days per month among patients with episodic and chronic migraine, the 120 mg and 240 mg doses of galcanezumab cut the average number of debilitating episodes by 4 and 3.8 days in one study for episodic migraine and 3.7 days and 3.6 days in another — compared to a placebo response that ran from 1.85 to 2.15 days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.